These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29222866)

  • 41. Outcomes of third heart transplants in pediatric and young adult patients: analysis of the United Network for Organ Sharing database.
    Friedland-Little JM; Gajarski RJ; Yu S; Donohue JE; Zamberlan MC; Schumacher KR
    J Heart Lung Transplant; 2014 Sep; 33(9):917-23. PubMed ID: 24861821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pediatric heart transplantation: 23-year single-center experience.
    Huebler M; Schubert S; Lehmkuhl HB; Weng Y; Miera O; Alexi-Meskishvili V; Berger F; Hetzer R
    Eur J Cardiothorac Surg; 2011 May; 39(5):e83-9. PubMed ID: 21354807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of circulating donor specific antibody to predict biopsy diagnosis of antibody-mediated rejection and to provide prognostic value after heart transplantation in children.
    Ware AL; Malmberg E; Delgado JC; Hammond ME; Miller DV; Stehlik J; Kfoury A; Revelo MP; Eckhauser A; Everitt MD
    J Heart Lung Transplant; 2016 Feb; 35(2):179-85. PubMed ID: 26520246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlations of lymphocyte subset infiltrates with donor-specific antibodies and acute antibody-mediated rejection in endomyocardial biopsies.
    Frank R; Dean SA; Molina MR; Kamoun M; Lal P
    Cardiovasc Pathol; 2015; 24(3):168-72. PubMed ID: 25440957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Late rejection episodes more than 1 year after pediatric heart transplantation: risk factors and outcomes.
    Webber SA; Naftel DC; Parker J; Mulla N; Balfour I; Kirklin JK; Morrow R;
    J Heart Lung Transplant; 2003 Aug; 22(8):869-75. PubMed ID: 12909466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis.
    Agbor-Enoh S; Jackson AM; Tunc I; Berry GJ; Cochrane A; Grimm D; Davis A; Shah P; Brown AW; Wang Y; Timofte I; Shah P; Gorham S; Wylie J; Goodwin N; Jang MK; Marishta A; Bhatti K; Fideli U; Yang Y; Luikart H; Cao Z; Pirooznia M; Zhu J; Marboe C; Iacono A; Nathan SD; Orens J; Valantine HA; Khush K
    J Heart Lung Transplant; 2018 Jul; 37(7):925-932. PubMed ID: 29500138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.
    Lobo LJ; Aris RM; Schmitz J; Neuringer IP
    J Heart Lung Transplant; 2013 Jan; 32(1):70-7. PubMed ID: 23260706
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparative analysis between survivors and nonsurvivors with antibody mediated cardiac allograft rejection.
    Gonzalez-Stawinski GV; Cook DJ; Chui J; Gupta S; Navia JL; Hoercher K; Taylor DO; Yamani MH; Starling RC; Smedira NG
    J Surg Res; 2007 Oct; 142(2):233-8. PubMed ID: 17727888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical significance of anti-HLA antibodies associated with ventricular assist device use in pediatric patients: A United Network for Organ Sharing database analysis.
    Magdo HS; Schumacher KR; Yu S; Gajarski RJ; Friedland-Little JM
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28568969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft Survival.
    Krisl JC; Alloway RR; Shield AR; Govil A; Mogilishetty G; Cardi M; Diwan T; Abu Jawdeh BG; Girnita A; Witte D; Woodle ES
    Transplantation; 2015 Oct; 99(10):2167-73. PubMed ID: 25856409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation.
    Vanderlaan RD; Manlhiot C; Edwards LB; Conway J; McCrindle BW; Dipchand AI
    Pediatr Transplant; 2015 Dec; 19(8):896-905. PubMed ID: 26381803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene expression profiling scores in dual organ transplant patients are similar to those in heart-only recipients.
    Carey SA; Tecson KM; Jamil AK; Felius J; Wolf-Doty TK; Hall SA
    Transpl Immunol; 2018 Aug; 49():28-32. PubMed ID: 29588161
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A retrospective review of the outcome of plasma exchange and aggressive medical therapy in antibody mediated rejection of renal allografts: a single center experience.
    Al-Badr W; Kallogjeri D; Madaraty K; Oliver D; Bastani B; Grossman BJ
    J Clin Apher; 2008; 23(6):178-82. PubMed ID: 19009629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methotrexate therapy for complex graft rejection in pediatric heart transplant recipients. The Pediatric Heart Transplant Team--Loma Linda.
    Chinnock R; Emery J; Larsen R; Baum M; Janner D; Razzouk A; Gundry S; Nehlsen-Cannarella S; Bailey L
    J Heart Lung Transplant; 1995; 14(4):726-33. PubMed ID: 7578182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients.
    Grupper A; AbouEzzeddine OF; Maleszewski JJ; Grupper A; Geske JR; Kremers WK; Kushwaha SS; Pereira NL
    Clin Transplant; 2018 Sep; 32(9):e13349. PubMed ID: 29998506
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ISHLT pathology antibody mediated rejection score correlates with increased risk of cardiovascular mortality: A retrospective validation analysis.
    Hammond MEH; Revelo MP; Miller DV; Snow GL; Budge D; Stehlik J; Molina KM; Selzman CH; Drakos SG; Rami A A; Nativi-Nicolau JN; Reid BB; Kfoury AG
    J Heart Lung Transplant; 2016 Mar; 35(3):320-325. PubMed ID: 26970471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late rejection occurred in recipients who experienced acute cellular rejection within the first year after heart transplantation.
    Imamura T; Kinugawa K; Nitta D; Fujino T; Inaba T; Maki H; Hatano M; Kinoshita O; Nawata K; Yao A; Kyo S; Ono M
    Int Heart J; 2015; 56(2):174-9. PubMed ID: 25740393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors for the development of donor-specific antibodies after pediatric heart transplantation.
    Godown J; Slaughter JC; Fossey SC; McKane M; Dodd DA
    Pediatr Transplant; 2015 Dec; 19(8):906-10. PubMed ID: 26412798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
    Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
    Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.